Soleno Therapeutics, Inc. (NASDAQ: SLNO) Q2 2025 Earnings | 08/07/2025

About this video

Soleno Therapeutics reported its second-quarter 2025 financial results, marking the first quarter of revenue following the successful U.S. launch of VYKAT XR, an FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome (PWS). The company generated net product revenue of $32.7 million in Q2 2025, driven primarily by strong sales of VYKAT XR. This significantly exceeded market expectations and underscored robust early adoption. The company posted a net loss of $4.7 million, or $0.09 loss per share, a sharp improvement from a net loss of $21.9 million, or $0.57 loss per share, in the same quarter a year ago. Gross profit stood at approximately $32.0 million, supported by low cost of goods sold at $0.7 million. Research and development expenses decreased year-over-year to $9.1 million, while selling, general, and administrative expenses rose to $28.2 million, reflecting investments related to the commercial launch of VYKAT XR. Operational highlights included the receipt of 646 patient start forms and engagement from 295 unique prescribers, underscoring strong initial uptake. Insurance coverage now includes approximately 33% of U.S. insured lives for VYKAT XR, surpassing typical rare disease launch coverage. The company also submitted and received EMA validation for a Marketing Authorization Application for VYKAT XR in Europe, signaling strategic expansion efforts. Soleno strengthened its financial position with $293.8 million in cash and equivalents at quarter-end, supplemented by a $230 million gross proceeds raise in July 2025. This robust liquidity supports ongoing commercialization and regulatory efforts. Management expressed optimism about the product’s market reception and emphasized continued focus on expanding market presence, advancing regulatory filings in Europe, and managing the rising costs associated with commercialization. Risks include ongoing operational expenses tied to the market launch and potential challenges related to scaling access and payer negotiations. About Inside Ticker: Inside Ticker delivers timely, in-depth financial news and earnings analysis to empower investors with actionable insights on global companies across sectors. For comprehensive video analysis and real-time updates, visit https://www.insideticker.com/. #SolenoTherapeutics #SLNO #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #EPS #Growth #RareDisease #Pharmaceuticals #Biotech #VYKATXR #PraderWilliSyndrome #DrugLaunch #ClinicalTrial #FDAApproval #HealthcareStocks #BiotechInvesting #LifeSciences #PharmaNews #PatientCare #BiotechGrowth #InvestorUpdates #Medication #FDA #PWS #HealthcareInnovation #GlobalExpansion #EMAApproval #RDRugs #SpecialtyPharma #StockMarketNews #InsideTicker